Pfizer Inc. (PFE) — closed signal from January 5, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 5, 2026.
Predicted vs. what happened
What happened
Reached its target in 85 days.
The thesis — published January 5, 2026
Pfizer is seen as a safer pick because it pays dividends, which can bring steady buyers as investors seek income into 2026. Expect a modest short-term bounce if sentiment improves rather than a big revaluation. The main things to watch are drug pipeline news and competitors, which can quickly change the stock's direction.
Primary drivers
- Dividend payouts can draw income-focused investors
- Big pharma status helps steady a portfolio in volatile markets
- Positive pipeline or guidance can prompt a short-lived rally
- Negative competitor news can quickly reverse gains
How it played out
PFE: target reached in 85 days
Lyra published PFE at $25.26 on 2026-01-05, with 12% expected growth and a $28.29 target. The thesis pointed to dividend payouts, big pharma status, possible pipeline or guidance news, and competitor news as the main items that could shape the move.
Inside the window, PFE reached a $28.75 peak on 2026-04-02, above the $28.29 target. It took 85 days to get there. The peak gain was 13.8%. The stock ended the window at $28.32, still above the target. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.